The PROKR2 antibody is a tool used to detect and study the prokineticin receptor 2 (PROKR2), a G protein-coupled receptor (GPCR) that binds prokineticin peptides (PROK1 and PROK2). PROKR2 plays critical roles in diverse physiological processes, including reproductive function, neurodevelopment, circadian rhythm regulation, and angiogenesis. It activates downstream signaling pathways, such as PKC and MAPK, influencing cell proliferation, migration, and differentiation. Mutations in the PROKR2 gene are linked to human disorders like hypogonadotropic hypogonadism (HH) and Kallmann syndrome (KS), characterized by delayed puberty and anosmia. Aberrant PROKR2 expression is also implicated in cancer progression, notably in glioblastoma and colorectal cancer.
PROKR2 antibodies, often polyclonal or monoclonal, are designed for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to analyze PROKR2 expression, localization, and regulation in tissues or cell lines. These antibodies aid in exploring PROKR2's role in disease mechanisms and normal physiology. Validation includes testing specificity via knockout controls or siRNA knockdown. Researchers use PROKR2 antibodies to investigate its interaction with ligands, receptor trafficking, and potential therapeutic targeting. Their development supports advancing diagnostics and treatments for PROKR2-related disorders, emphasizing their importance in both basic research and clinical contexts.